November 2023
1. DODICK DW, Goadsby PJ, Schwedt TJ, Lipton RB, et al
   Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
   Lancet. 2023 Nov 15:S0140-6736(23)01683-5. doi: 10.1016/S0140-6736(23)01683.
   

   >> Share

   
   July 2023
2. POZO-ROSICH P, Ailani J, Ashina M, Goadsby PJ, et al
   Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
   Lancet. 2023 Jul 26:S0140-6736(23)01049-8. doi: 10.1016/S0140-6736(23)01049.
   

   >> Share

   
   
3. HAANES KA, Edvinsson L
   Atogepant, the first oral preventive treatment for chronic migraine.
   Lancet. 2023 Jul 26:S0140-6736(23)01462-9. doi: 10.1016/S0140-6736(23)01462.
   

   >> Share

   
   March 2021
4. ASHINA M, Katsarava Z, Do TP, Buse DC, et al
   Migraine: epidemiology and systems of care.
   Lancet. 2021 Mar 25. pii: S0140-6736(20)32160.
   

   >> Share

   
   
5. ASHINA M, Buse DC, Ashina H, Pozo-Rosich P, et al
   Migraine: integrated approaches to clinical management and emerging treatments.
   Lancet. 2021 Mar 25. pii: S0140-6736(20)32342.
   

   >> Share

   
   
6. ASHINA M, Terwindt GM, Al-Karagholi MA, de Boer I, et al
   Migraine: disease characterisation, biomarkers, and precision medicine.
   Lancet. 2021 Mar 25. pii: S0140-6736(20)32162.
   

   >> Share

   
   December 2020
7. CROOP R, Lipton RB, Kudrow D, Stock DA, et al
   Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2020 Dec 15. pii: S0140-6736(20)32544.
   

   >> Share

   
   
8. EDVINSSON L
   Oral rimegepant for migraine prevention.
   Lancet. 2020 Dec 15. pii: S0140-6736(20)32624.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share